Awiqli, a once-weekly basal insulin, now has US approval for children aged 10 and older with type 2 diabetes. The FDA announced the expanded indication on 23 October 2026. Adults with type 2 diabetes were already included in its US indication.
The change adds a treatment option, not a cure. For families managing insulin treatment, fewer background injections may be useful. However, the evidence supporting the paediatric approval needs explaining, and low blood sugar and dosing mistakes remain important risks.
What has the FDA approved?
The FDA announcement covers Awiqli, also called insulin icodec-abae, alongside diet and exercise to improve blood glucose control in people aged 10 and older with type 2 diabetes. It is the first once-weekly insulin approved in the US for children with this condition.
This is a US regulatory decision. It does not establish the same paediatric indication, availability or funding in the UK, Saudi Arabia or another country. Families outside the US need information about their own regulator and local services, rather than assuming that a US headline applies to them.
What does basal insulin do?
Basal insulin supplies background insulin between meals and overnight. It differs from the faster-acting insulin some people need around meals. The NHS explanation of long-acting insulin describes this distinction: background treatment and mealtime treatment have different jobs.
Changing the frequency of basal treatment does not mean that every other injection disappears. A person may still need other diabetes medicines, including mealtime insulin if prescribed. It also does not remove the need for glucose monitoring.
Awiqli is an insulin medicine, not a GLP-1 medicine. A weekly schedule alone does not make two injectable treatments interchangeable. The name, pen and instructions matter, particularly when more than one injectable medicine is used.
What evidence supports use in children?
The October 2026 US prescribing information describes evidence from adequate, well-controlled adult studies together with a paediatric pharmacokinetic study. Pharmacokinetics means how a medicine is absorbed and handled by the body.
The registered paediatric study, NCT05790681, enrolled 18 young people with type 2 diabetes. It was a phase 1, open-label, single-group study, not a randomised comparison against daily insulin. Participants were aged 10 to under 18 and already receiving insulin treatment.
They received one study dose and were followed for five weeks afterwards. Its main measurements concerned insulin levels in the blood, including the peak level and overall exposure. These were not measurements of years of diabetes complications, school attendance or quality of life.
The FDA reports faster absorption after the first dose in children than in adults. Mathematical modelling predicted similar blood levels after repeated doses. This helped bridge adult evidence to the younger population.
That is different from demonstrating, in a large long-term trial in children, that weekly insulin produces better glucose control or fewer severe hypos than daily insulin. Those superiority claims should not be inferred from this approval. Safety and effectiveness below age 10 have not been established in the US label.
Why might another option be useful?
The practical attraction is fewer basal injection occasions. Novo Nordisk’s announcement describes a reduction from daily basal injections to once weekly. That may suit some routines, but the manufacturer has a commercial interest and its expectations are not proof of better everyday outcomes for every family.
Type 2 diabetes can occur in childhood. As NIDDK explains, it involves insufficient insulin, insulin not working effectively, or both. Treatment can include more than one medicine as well as support with eating patterns, activity and other health needs.
A useful treatment discussion therefore considers the whole care plan, not injection frequency alone. A simpler timetable is only helpful if the medicine can be used safely and fits the person’s needs.
What are the important safety limits?
Low blood sugar, or hypoglycaemia, remains the central insulin risk. Severe episodes can cause seizures, unconsciousness or death. The Awiqli label also warns about medication errors, accidental overdose, high blood sugar during treatment changes, low potassium, serious allergy and fluid retention or heart failure when used with thiazolidinedione medicines.
Other reported adverse effects include injection-site reactions, changes in fat tissue at injection sites, itching, rash, swelling and weight gain. A less frequent injection is not a guarantee of fewer side effects.
Starting or switching insulin requires close medical supervision and increased glucose monitoring. Do not use a news article to calculate a new dose, convert a daily dose into a weekly one, or decide how to handle a missed injection. Follow the individual instructions from the prescribing team and the current medicine leaflet.
The manufacturer stresses checking the product label and prescribed dose, receiving pen training and never withdrawing insulin from the Awiqli pen into a syringe. These precautions matter because products and dosing schedules can be confused.
When is urgent help needed?
The NHS hypoglycaemia guide lists shaking, sweating, dizziness, irritability and confusion among possible symptoms. Families should have a clear, age-appropriate hypo plan from their diabetes team, including what to do when the person can safely swallow.
If someone has a seizure, becomes unconscious, cannot swallow safely or is not responding normally, call local emergency services. Do not give food or drink to an unconscious person. Use prescribed emergency glucagon if available and you have been trained, while following the emergency team’s instructions.
Questions to bring to a diabetes appointment
- Does the local indication cover this person’s age and type of diabetes?
- Would weekly basal treatment suit their needs, and what alternatives are available?
- What monitoring, pen training and hypo support would be needed?
- Which other medicines would continue, and who should be contacted about missed doses or illness?
For wider context, our guide to whole-person type 2 diabetes care explains why treatment decisions consider more than a glucose number. The new US approval broadens choice; it does not make weekly insulin the right treatment for everyone.